DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring, MD 20993

DMF 033023

DMF ACKNOWLEDGEMENT

HAINAN POLY PHARM. CO., LTD.
Attention: ZHOU XUELAI, VICE GEN. MANAGER – REG. AFFAIRS
GUILINYANG ECONOMIC DEVELOPMENT AREA
HAIKOU, HAINAN - 571127, CHINA

Dear Zhou Xuelai,

The Food and Drug Administration acknowledges receipt of the following Drug Master File (DMF) submission:

DMF NUMBER ASSIGNED:	033023
DATE OF SUBMISSION:	SEPTEMBER 6, 2018
DMF TYPE:	II
SUBJECT (TITLE):	SODIUM NITROPRUSSIDE
HOLDER:	HAINAN POLY PHARM. CO., LTD.
SUBMITTED BY:	HAINAN POLY PHARM. CO., LTD.
AGENT:	CARDINAL HEALTH REGULATORY SCIENCES

All subsequent correspondence to this DMF should be identified with the information as provided above.

Your DMF will be reviewed only in connection to a New Drug Application, Abbreviated New Drug Application, Investigational New Drug Application, Biological License Application, New Animal Drug Application, Abbreviated New Animal Drug Application, Investigational New Animal Drug Application, or DMF it is intended to support when a Letter of Authorization (LOA) is submitted to the DMF and a copy of the LOA is submitted in the application e.g., NDA, that references the DMF.

You are responsible for compliance with 21 CFR314.420. See "The Guideline for Drug Master Files" http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/ucm073164.htm

You are required to submit all changes in information regarding the DMF (21 CFR 314.420(c)). In particular the FDA must be notified of any changes in the holder name or ownership and/or the agent and/or the name of the contact person.

The types of information to be submitted may be found at the DMF Web Site. See "**Submission of Amendments, Annual Reports, and Letters of Authorization.**

You are expected to:

- Adhere to the statement of commitment you have provided.
- Provide the following submissions to the DMF:
    a. Letters of Authorization (LOAs) granting permission to a third party (authorized party) to reference the DMF and for FDA to review the DMF. Listing an authorized party in the Annual Report (see below) is not sufficient to authorize that party to reference the DMF. Submission of a copy of the LOA to the authorized party without submitting the original LOA to the DMF is also not sufficient to authorize that party to reference the DMF.
    b. Annual Reports to the DMF containing:
        i. Date(s) of the amendment(s) reporting changes since the last Annual Report or the original DMF filing date, whichever is most recent or a statement that no amendments have been submitted since the last Annual Report or the original DMF filing date, whichever is most recent.
        ii. A complete list of all parties authorized to make reference to the DMF, identifying by name, reference number, volume, date, and page number the information that each person is authorized to incorporate and the date of the LOA or a statement that there are no Authorized Parties.
        iii. A list of all parties whose authorization has been withdrawn, if applicable.
        iv. Holder signed DMF Statement of Commitment stating that the DMF is current and the holder will comply with the statements made in it.

Submissions containing multiple types of information e.g. administrative changes, an annual report, or changes in technical information should specify the different types of information in the header in the cover letter.

Electronic submissions that are 10GB or smaller in size must be submitted through the Electronic Submission Gateway (ESG). Submissions that are over 10GB may be submitted on physical media (such as compact disc)[1] to the following address:

Food and Drug Administration
Center for Drug Evaluation and Research
Central Document Room
Drug Master File Staff
5901-B Ammendale Road
Beltsville MD 20705-1266

If you have any questions, please email dmfquestion@fda.hhs.gov

[1] See FDA eCTD Web Page for further information.
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm153574.htm.

Sincerely,
{See appended electronic signature page}
Vathsala Selvam
Drug Master Files
Division of Life Cycle API/ONDP/OPQ
Center for Drug Evaluation and Research
Food and Drug Administration

CC:
CARDINAL HEALTH REGULATORY SCIENCES
Attention: BOYD LUND, DIRECTOR
7400 WEST 110TH STREET, SUITE 300
OVERLAND PARK, KS 66210

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

VATHSALA D SELVAM
09/06/2018